Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
COGT•Commercial supply agreement with Hovione
-
Cogent Biosciences, Inc. COGT.O:
-
Cogent Biosciences enters commercial supply agreement with Hovione on Sept. 1, 2026 - SEC filing
-
Cogent Biosciences to purchase minimum percentages of bezuclastinib products from Hovione - SEC filing
-
Agreement effective for five-year term with automatic two-year renewals - SEC filing
Related News
Nu Holdings to host first investor day, outlining long-term strategy and growth priorities
NU•
Capital Southwest Increases Corporate Credit Facility To $595 Million And Extends Maturity To September 2031
CSWC•
